Albemarle Corporation filings document operating results, material events, governance matters, shareholder voting items, and capital-structure disclosures for a public specialty chemicals and critical materials company. Form 8-K reports cover quarterly financial results, credit agreement amendments, debt-related actions, board appointments, officer transitions, and completed portfolio transactions.
Proxy materials describe director elections, committee governance, executive compensation, shareholder proposals, and voting procedures. Albemarle's filing record also documents the completed disposition of a controlling stake in Ketjen, retained ownership interests, integration of Performance Catalyst Solutions, and financing arrangements tied to the company's global lithium, bromine and specialty product businesses.
Albemarle Corporation (ALB) – Form 4 insider filing dated 07/03/2025
Non-employee director Alejandro Daniel Wolff reported two routine equity transactions carried out under the company’s 2023 Stock Compensation and Deferral Election Plan for Non-Employee Directors:
- Common stock dividend equivalents: 37 shares were credited on 07/01/2025 as dividend equivalents on a prior equity award that vested the same day. These shares were acquired at $0 cost, bringing the director’s directly held common stock to 12,539 shares.
- Phantom stock grant: 2,725 phantom stock units (1-for-1 convertible into common shares) were awarded on 07/01/2025. The units vest on 07/01/2026 and have no stated expiration date. Including this grant and associated dividend equivalents, the director now holds 6,278 phantom stock units.
No sales or dispositions were reported. The transactions were made at $0 price and do not involve open-market purchases or sales. As Wolff remains on the board, these grants represent standard annual director compensation and dividend accruals rather than signal-bearing insider buying or selling.
Overall, the filing reflects normal course equity accrual that slightly increases insider alignment but is immaterial to Albemarle’s share count or valuation. There is no indication of strategic intent or upcoming corporate events.
Albemarle Corporation (ALB) – Form 4 insider transaction filing
Director Dean Seavers reported two equity awards dated 1 July 2025:
- 2,725 common shares granted under the 2023 Stock Compensation and Deferral Election Plan for Non-Employee Directors; the award vests on 1 July 2026.
- 37 additional shares issued as accrued dividends on a July 2024 award that vested in full on 1 July 2025.
No shares were sold and no derivative securities were transacted. Following the awards, Seavers’ total direct beneficial ownership rose to 12,021 common shares. The transactions were effected at a stated price of $0, reflecting their nature as board compensation rather than open-market purchases.
The filing is routine for annual director compensation but does increase insider equity alignment and signals continued board participation in Albemarle’s long-term incentive structure.